

## REFERENCES

1. American Association of Blood Banks. Guidelines for Informed Consent for Transfusion Medicine. AABB Press, Bethesda, MD, 2006.
2. American Association of Blood Banks. Technical Manual, 19th Ed. Fung, MK. AABB, Bethesda, MD, 2017.
3. American Association of Blood Banks. The evolving paradigm of patient blood management. *Transfusion* 2014;54:2581-2790.
4. American Association of Blood Banks. Transfusion Reactions 4th Ed. Popovsky MA. AABB Press, Bethesda, MD, 2012.
5. Anderson D, Ali K, Blanchette V et al. Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions. *Transfus Med Rev* 2007; 21 (Suppl 1): S9-S56.
6. Arnold DM, Molinaro G, Warkentin TE et al. Hypotensive Transfusion Reactions can Occur with Blood Products that are Leukoreduced before Storage. *Transfusion* 2004; 44: 1361-1366.
7. Aubuchon JP, Puca K, Saxena S et al. Getting Started in Patient Blood Management. AABB, Bethesda, MD, 2011. Web. <[www.aabb.org/pbm/Documents/112024.pdf](http://www.aabb.org/pbm/Documents/112024.pdf)>
8. Aubuchon, JP. Managing Change to Improve Transfusion Safety. *Transfusion* 2004; 44.9: 1377-1383.
9. Aubuchon, JP. The Role of Transfusion Medicine Physicians. *Arch Path Lab Med*, 1999; 123.8: 663-667.
10. Barros MMO, Blajchman MA, Bordin JO. Warm Autoimmune Hemolytic Anemia: Recent Progress in Understanding the Immunobiology and the Treatment. *Transfus Med Rev* 2010; 24:195-210.
11. Benson AB, Moss M, Silliman CC. Transfusion-Related Acute Lung Injury (TRALI): A Clinical Review with Emphasis on the Critically Ill. *Br J Haematol* 2009; 147: 431-443.
12. Berger M. Choices in IgG Replacement Therapy for Primary Immune Deficiency Diseases: Subcutaneous IgG vs. Intravenous IgG and Selecting an Optimal Dose. *Curr Opin All Clin Immunol* 2011;11: 532-538.
13. Berte LM, Nevalainen DE. Quality Systems for the Laboratory. ASCP Press. Chicago, IL, 2000.
14. Bhella S, Gerard L, Lin Y et al. Obstetric and Trauma Database Review at a Single Institution Finds the Optimal Maternal Age Restriction for the Transfusion of D Negative Blood to Women Involved in Trauma to be 45 Years. *Transfusion* 2012; 52.11: 2488-2489.
15. Blackall DP. How Do I Approach Patients with Warm-Reactive Antibodies?. *Transfusion* 2011; 51.1: 14-17.
16. Blajchman M, Goldman MA, Freedman J, Sher GD. Proceedings of a Consensus Conference: Prevention of Post-transfusion CMV Infection in the Era of Universal leukoreduction. *Transfus Med Rev* 2001; 15.1: 1-20.
17. Bodnaruk ZM, Wong CJ, Thomas MJ. Meeting the Clinical Challenge of Care of Jehovah's Witnesses. *Transfus Med Rev* 2004;18: 105-116.
18. Brecher ME, Hay SN. Bacterial Contamination of Blood Components. *Clin Microbiol Rev* 2015;18:195-204.
19. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the Use of Fresh-Frozen Plasma, Cryoprecipitate and Cryosupernatant. *Br J Haematol* 2004; 126:11-28.
20. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the Use of Platelet Transfusions. *Br J Haematol* 2017; 176: 365-394.
21. British Committee for Standards in Haematology. Guidelines on Transfusion for Fetuses, Neonates and Older Children. *Br J Haematol* 2016;175: 784-828.



22. Callum JL et al. Reporting of Near-miss Events for Transfusion Safety. *Transfusion* 2001;41.10: 1204-1211.
23. Callum JL, Dzik WH. The Use of Blood Components Prior to Invasive Bedside Procedures: A Critical Appraisal In *Transfusion Therapy: Clinical Principles and Practice*, 3rd Ed. Mintz PD. AABB, Bethesda, MD, 2011; 1-35.
24. Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. *Transfus Med Rev* 2009;23.3: 177-188.
25. Callum JL, Pinkerton PH, Lima A et al. *Bloody Easy 4: Blood Transfusions, Blood Alternatives and Transfusion Reactions. A Guide to Transfusion Medicine*, 4th ed. Ontario Regional Blood Coordinating Network, 2016.
26. Canadian Blood Services. Circular of Information for the Use of Human Blood and Blood Components. Web. <<http://blood.ca/en/hospitals/circular-information>>
27. Canadian Blood Services. Clinical Guide to Transfusion. Web. <<http://professionaleducation.blood.ca/en/transfusion>>
28. Canadian Blood Services. Plasma Protein Products. Canadian Blood Services, 2011. Web. <<https://blood.ca/en/hospitals/plasma-protein-products>>
29. Canadian Society of Transfusion Medicine. Informed Consent: Position Paper. Web. <<http://www.transfusion.ca>>
30. Canadian Society of Transfusion Medicine. Standards for Hospital Transfusion Services. Version 4. 2017. Web. <<http://www.transfusion.ca/Resources/Standards>>
31. Canadian Standards Association. Standards for Blood and Blood Components. CAN/CSA-Z902-15.
32. Carson JL, Guyatt G, Heddle N et al. Clinical Practice Guidelines from the AABB. Red Blood Cell Transfusion Thresholds and Storage. *JAMA* 2016; 316: 2025-2035.
33. Cherin P, Marie I, Michallet EP et al. Management of adverse events in the treatment of patients with immunoglobulin therapy. *Autoimm Rev* 2016;15: 71-81.
34. Chow S, Salmasi G, Callum JL, Lin Y. Trimming the Fat with an IVIG Approval Process. *Transfus Aph Sci* 2012;46: 349 – 352.
35. Clifford L, Jia Q, Subramanian A et al. Anesthesiology. Risk factors and clinical outcomes associated with perioperative transfusion-associated circulatory overload. *Anesthesiology* 2017; 126:409-418.
36. Clinical Guidelines for Immunoglobulin Use. 2nd ed. United Kingdom Department of Health, 2011. Web. <<http://www.gov.uk/government/publications/clinical-guidelines-for-immunoglobulin-use-second-edition-update>>
37. Cohen R, Escorcía A, Tasmin F et al. Transfusion. Feeling the burn: the significant burden of febrile nonhemolytic transfusion reactions. *Transfusion* 2017;57:1674-1683.
38. Cohn CS. Transfusion support issues in hemopoietic stem cell transplantation. *Cancer Control* 2015;22:52-59.
39. Cyr C, Eastland T, Blais C et al. Bradykinin Metabolism and Hypotensive Transfusion Reactions. *Transfusion* 2001; 41: 136-150.
40. Dananayake T, Sime PJ, Phipps R, Blumberg N. Transfusion Therapy in Critical Care. In *Transfusion Therapy. Clinical Principles and Practice*, 3rd Ed. Mintz PD. AABB Press, Bethesda, MD, 2011; 323-337.
41. Daniel-Johnson J, Schwartz J. How Do I Approach ABO-Incompatible Hemopoietic Progenitor Cell Transplantation?. *Transfusion* 2011; 51: 1143-1149.
42. Davenport RD. Management of Transfusion Reactions. *Transfusion Therapy. Clinical Principles and Practice*, 3rd Ed. Mintz PD. AABB Press, Bethesda, MD, 2011;1-35.
43. Davis RE, Vincent CA, Murphy MF. Blood Transfusion Safety: The Potential Role of the Patient. *Transfus Med Rev* 2011;25: 12-23.



44. Delaney M, Wendel S, Bercovitz RS et al. Transfusion reactions: prevention, diagnosis, and treatment.
45. Disaster Operations Handbook, Version 2. American Association of Blood Banks, October 2008. Web. <[www.aabb.org](http://www.aabb.org)>
46. Domen RE. The Transfusion Medicine Service is an Integral and Important Component of the Hospital and Should Not be Outsourced. *Transfus Sci* 1997; 18: 565-573.
47. Dunbar NM, Ornstein DL, Dumont LJ. ABO incompatible platelets: risks vs. benefit. *Curr Opin Hematol* 2012;19:475-479.
48. Dzik WH, Blajchman MA, Fergusson D et al. Clinical review: Canadian National Advisory Committee on Blood and Blood Products – Massive Transfusion Consensus Conference 2011: Report of the Panel. *Crit Care* 2011;15.6: 242.
49. Dzik WH. How I do it: platelet support for refractory patients. *Transfusion* 2007; 47.3: 374-378.
50. Eastland T. Vasoactive Mediators and Hypotensive Transfusion Reactions. *Transfusion* 2007;47: 369-372.
51. Expert Working Group Guidelines for Red Blood Cell and Plasma Transfusion for Adults and Children. *CMAJ* 1997;156: S1-S24.
52. Farrell AM, Brazier M. Consent for Blood Transfusion. *Brit Med J* 2010;341: 539-541.
53. Feasby T, Banwell B, Benstead T et al. Guidelines on the Use of Intravenous Immune Globulin for Neurologic Conditions. *Transfus Med Rev* 2007; 21 Suppl 1: S57-S107.
54. Fung Kee Fung K, Eason E, Crane J et al. Prevention of Rh Alloimmunization. *J Obst Gyn Can* 2003;25: 765-773.
55. Garratty G. Advances in Red Blood Cell Immunology 1960 to 2009. *Transfusion* 2010; 50.3: 526-535.
56. George JN, Woolf SH, Raskob GE et al. Idiopathic Thrombocytopenic Purpura: A Practice Guideline Developed by Explicit Methods for the American Society of Hematology. *Blood* 1996; 88: 3-40.
57. Gilstad CW. Anaphylactic transfusion reactions. *Curr Opin Hematol* 2003; 10: 419-423.
58. Goldman M, Webert KE, Arnold DM et al. Proceedings of a Consensus Conference: Towards an Understanding of TRALI. *Transfus Med Rev* 2005;19: 2-31.
59. Goodnough LT, Daniels K, Wong AE et al. How We Treat: Transfusion Medicine Support of Obstetric Services. *Transfusion* 2011; 51: 2540-2548.
60. Goodnough LT, Shander A, and Spence R. Bloodless Medicine: Clinical Care Without Allogeneic Blood Transfusion. *Transfusion* 2003; 43.5: 668-676.
61. Goodnough LT. What is a Transfusion Medicine Specialist?. *Transfusion* 1999; 39.9: 1031-1033.
62. Gorlin JB, Mintz PD. Transfusion Associated Graft vs. Host Disease. *Transfusion Therapy 3rd Ed.* Mintz PD. AABB, Bethesda, MD, 2011;1-35.
63. Government of Canada. [Commission of Inquiry on the Blood System in Canada, final report] Commissioner, Horace Krever 1997.
64. Guideline for Implementation of Informed Consent for Blood and Blood Products. Provincial Blood Coordinating Office, British Columbia, 1999. Web. <<http://www.pbco.ca/>>
65. Guideline on the Administration of Blood Components. British Society of Haematology 2017. Web <<http://www.b-s-h.org.uk/guidelines/guidelines/administration-of-blood-components/>>
66. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. *Int Immunopharmacol* 2006;6: 535-542.



67. Hume H, Kronklick JB, Blanchette VS. Review of the Literature on Allogeneic Red Blood Cell and Plasma Transfusions in Children. *CMAJ* 1997; 156.11: S41-S49.
68. Informed Consent Card and Mobile Application. Ontario Regional Blood Coordinating Network. 2014. Web. <<http://www.transfusionontario.org/>>
69. Institute for Quality Management in Healthcare. The IQMH Requirements and Guidance Information for Medical Laboratories, 2018 Web. <<https://iqmh.org>>
70. Immune Globulin Toolkit for Ontario. Ontario Regional Blood Coordinating Network. 2018. Web. <[www.transfusionontario.org](http://www.transfusionontario.org)>
71. Intravenous Immune Globulin. Provincial Blood Coordinating Office, British Columbia. Web. <[www.pbco.ca](http://www.pbco.ca)>
72. Josephson CD et al. Significant numbers of apheresis-derived group O platelet units have “high titre” anti-A/A,B: implications for transfusion policy. *Transfusion* 2004;44:805-808.
73. Josephson CD, Su LL, Hillyer KL, Hillyer CD. Transfusion in the Patient with Sickle Cell Disease: A Critical Review of the Literature and Transfusion Guidelines. *Transfus Med Rev* 2007; 21: 118-133.
74. Juskewitch JE, Norgan AP, De Goey SR et al. How do I...manage the platelet-refractory patient? *Transfusion* 2017;57:2828-2835.
75. Kaplan HS, Callum JL, Rabin Fastman B, Merkley LL. The Medical Event Reporting System for Transfusion Medicine: Will it Help Get the Right Blood to the Right Patient. *Transfus Med Rev* 2002; 16.2: 86-102.
76. Kopolovic I, Ostro J, Tsubota H et al. A systematic review of transfusion-associated graft-versus-host disease. *Blood* 2015;126:406-414.
77. Larsson LG, Welsh VJ, Ladd DJ. Acute intravascular hemolysis secondary to out-of-group platelet transfusion. *Transfusion* 2000;40: 902-906.
78. Lau W. Neonatal and Pediatric Transfusion. *Clinical Guide to Transfusion*. Canadian Blood Services, 2017. Web. <<https://professionaleducation.blood.ca/en/transfusion/clinical-guide/neonatal-and-pediatric-tr>>
79. Lieberman L, Maskens C, Cserti-Gazdewich C et al. A retrospective review of patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload. *Transfus Med Rev* 2013;27:206-212.
80. Lima A. *Bloody Easy Blood Administration: A Handbook for Health Professionals*, 2nd Ed. Ontario Regional Blood Coordinating Network. 2015
81. Lin Y, Callum JL. Emergency Reversal of Warfarin Anticoagulation. *CMAJ* 2004; 182: 2004.
82. Lin Y, Moltzan CJ, Anderson DR. The Evidence for the Use of Recombinant Factor VIIa in Massive Bleeding: Revision of the Transfusion Policy Framework. *Transfus Med* 2012; 22: 383-394.
83. Lozano M, Cid J. The Clinical Implications of Platelet Transfusions Associated with ABO or Rh(D) Incompatibility. *Transfus Med Rev* 2003;17: 57-68.
84. Majeed A, Agren A, Holmstrom et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. *Blood* 2017; 130: 1706-1712.
85. Martin A, Lavoie L, Goetghetbeur M, Schellenberg R. Economic Benefits of Subcutaneous Rapid Push Versus Intravenous Infusion Therapy in Adult Patients with Primary Immune Deficiency. *Transf Med* 2013;23:55-60.
86. McFarland JG. Post transfusion purpura. In *Transfusion Reactions* 3rd Ed. Ed. Popovsky MA. AABB Press, Bethesda, MD. 2007;275-299.



87. Michael M, Elliot EJ, Craig JC et al. Interventions for Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura: a systematic Review of Randomized Controlled Trials. *Amer J Kid Dis* 2009;53: 259-272.
88. Mollison's Blood Transfusion in Clinical Medicine, 12th Ed. Klein HG. Blackwell Scientific Publications, 2014:432-433.
89. Moltzan CJ, Anderson DA, Callum JL et al. The Evidence for the Use of Recombinant Factor VIIa in Massive Bleeding: Development of a Transfusion Policy Framework. *Transf Med* 2008;18: 112-120.
90. Murphy MF, Stanworth SJ, Yazer M. Transfusion Practice and Safety: Current Status and Possibilities for Improvement. *Vox Sang* 2011;100: 46-59.
91. Narick C, Triulzi DJ, Yazer MH. Transfusion-Associated Circulatory Overload after Plasma Transfusion. *Transfusion* 2012;52.1: 160-165.
92. National Advisory Committee on Blood and Blood products. NAC statement regarding appropriateness of use of Cytomegalovirus (CMV) Seronegative Versus CMV safe product(February 14, 2017) Web. [www.nacblood.ca/resources/guidelines/CMV.html](http://www.nacblood.ca/resources/guidelines/CMV.html).
93. National Advisory Committee on Blood and Blood Products. National Plan for the Mangement of Shortages of Labile Blood Components and the Emergency Framework for Rationing of Blood for Massively Bleeding Patients During a Red Phase Blood Shortage. Web. <[www.nacblood.ca/resources/shortages-plan/index.html](http://www.nacblood.ca/resources/shortages-plan/index.html)>
94. National Advisory Committee on Blood and Blood Products. Recommendations for use of Prothrombin Complex Concentrates in Canada. 2014. Web. [www.nacblood.ca/resources/guidelines/PCC-recommendations-final-2014-05-16.pdf](http://www.nacblood.ca/resources/guidelines/PCC-recommendations-final-2014-05-16.pdf).
95. National Advisory Committee on Immunization. Canadian Immunization Guide, 7th ed. The Public Health Agency of Canada, 2006. Web. <<https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html>>
96. National Institutes of Health. Evidence-based management of sickle cell disease: expert panel report, 2014. US Department of health and Human Services, National Heart, Lung and Blood Institute. Web. <<https://www.nhlbi.nih.gov/guidelines>>
97. Ness PM. How do I encourage clinicians to transfuse mismatched blood to patients with autoimmune hemolytic anemia in urgent situation? *Transfusion* 2006;46: 1859-1862.
98. Noga T, Bruce AAK, Blain H et al. Four-factor prothrombin complex concentrates in paediatric patients- a retrospective case series. *Vox Sang* 2016;110:253-257.
99. Ontario Contingency Plan for Management of Blood Shortages and Contingency Planning Toolkit. Ministry of Health and Long Term Care, Ontario Regional Blood Coordinating Network V3, 2016. Web. <<http://transfusionontario.org/en/download/ontario-hospital-toolkit-for-emergency-blood-management/>>
100. Ontario Regional Blood Coordinating Network. Transfusion Committee Handbook V2, 2016. Web. <<http://transfusionontario.org/en/download/transfusion-committee-handbook-version-2/>>
101. Pediatric Transfusion: A Physician's Handbook, 4th Ed. Rosoff SD. AABB Press, Bethesda, MD. 2014.
102. Perrotta PL, Snyder EL. Non-infectious Complications of Transfusion Therapy. *Blood Rev* 2001; 15: 69-83.
103. Petz LD, Garratty G. Immune Hemolytic Anemias. Churchill Livingstone, Philadelphia, PA. 2003.
104. Petz LD. Immunohematologic Problems Associated with Bone Marrow Transplantation. *Transfus Med Rev* 1987; 1:85-100.
105. Phekoo KH, Hambly H, Sehey SA et al. Audit of Practice in Platelet Refractoriness. *Vox Sang* 1997; 73: 81-86.
106. Pierce LR, Jain N. Risks Associated with the Use of Intravenous Immunoglobulin. *Transfus Med Rev* 2003;17: 241-251.



107. Pinkerton PH, Callum JL. Rationalizing the Clinical Use of Frozen Plasma. *CMAJ* 2010;182: 1019-1020.
108. Popovsky MA, Triulzi D. The Role of the Transfusion Medicine Consultant. *Amer J Clin Path* 1996;105: 798-801.
109. Popovsky MA. To Breathe or Not to Breathe – That is the Question. *Transfusion* 2010; 50.9: 2057-2062.
110. Prokopchuk-Gauk O, Solhz. CMV seronegative, irradiated and washed blood components. *Canadian Blood Services: Clinical Guide to Transfusion*. 2017; chapter 15.
111. Provincial Frozen Plasma and Prothrombin Complex Concentrate Audit Report. Ontario Regional Blood Coordinating Network, 2013. Web. <<http://transfusionontario.org/en/documents/?cat=frozen-plasma-audits-blood-utilizati>>
112. Public Health Agency of Canada. Transfusion Transmitted Injuries Surveillance System. User's Manual, V3.0. Minister of Health, Ottawa, November 2007. Web. <[www.phac-aspc.gc.ca](http://www.phac-aspc.gc.ca)>
113. Reading and Recording Gel Reactions using MTS Columns. Ontario Regional Blood Coordinating Network. Doc. GM.001. 2014. Web. <<http://transfusionontario.org/en/download/gm-001-reading-and-recording-gel-reactions-using-mts-columns/>>
114. Reading and Recording Hemagglutination Reactions, OTTRM. Ontario Regional Blood Coordinating Network. Doc. RT.001. 2014 Web. <http://transfusionontario.org/en/download/rt-001-reading-and-recording-hemagglutination-reactions/>
115. Recommendations for use of Prothrombin Complex Concentrates in Canada. National Advisory Committee on Blood and Blood Products, 2011. Web. <[www.nacblood.ca/resources/guidelines/nac-pcc-recommendations-june-2011-final.pdf](http://www.nacblood.ca/resources/guidelines/nac-pcc-recommendations-june-2011-final.pdf)>
116. Reid ME, Oyen R, Marsh WL. Summary of the Clinical Significance of Blood Group Alloantibodies. *Sem Hematol* 2000;37: 197-216.
117. Rock G, Anderson D, Clark W et al. Does Cryosupernatant Plasma Improve Outcome in Thrombotic Thrombocytopenic Purpura? No answer yet. *Br J Haematol* 2005; 129: 79-86.
118. Roseff SD, Luban NL, Manno CS. Guidelines for Assessing Appropriateness of Pediatric Transfusion. *Transfusion* 2002;42: 1398-1413.
119. Ruhl H, Bein G, Sachs UJH. Transfusion-associated graft-vs-host disease. *Transfus Med Rev* 2009; 23:62-71.
120. Sacher RA, Luban NLC, Strauss RG. Current Practice and Guidelines for Transfusion of Cellular Components in the Newborn. *Transfus Med Rev* 1989;3: 39-54.
121. Saxena S, Shulman IA. *The Transfusion Committee: Putting Patient Safety First*. AABB Press. Bethesda, MD, 2006.
122. Serious Hazards of Transfusion (SHOT). 2016 Annual SHOT Report, 2017. Web. <<https://www.shotuk.org/2016-annual-shot-report-published-12-july-2017/>>
123. Shehata N, Palda V, Bowen T et al. The Use of Immunoglobulin Therapy for Patients with Primary Immune Deficiency: An Evidence-Based Practice Guideline. *Transfus Med Rev* 2010; 24 (Suppl 1): S28-S50.
124. Shehata N, Palda VA, Meyer RM et al. The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline. *Transfus Med Rev* 2010; 24 (Suppl 1): S7-S27.
125. Shehata N, Tinmouth A, Naglie G et al. ABO-identical versus non-identical platelet transfusion: a systematic review. *Transfusion* 2009; 49: 2442-2453.
126. Slichter SJ. Transfusion and Bone Marrow Transplantation. *Transfus Med Rev* 1998; 2: 1-17.



127. Speiss BD. Treating Heparin Resistance with Antithrombin or Fresh Frozen Plasma. *The Ann Thor Surg* 2008;85: 2153-2160.
128. Stanger SHW, Yates N, Wilding RJ, Cotton S. Blood Inventory Management: Hospital Best Practice. *Transfus Med Rev* 2012;26: 153-163.
129. Stiem ER. Adverse effects of human immunoglobulin therapy. *Transfus Med Rev* 2013; 27: 171-178.
130. Strauss R. *Handbook of Pediatric Transfusion Medicine*. Elsevier Academic Press, San Diego CA, 2004.
131. Tinegate A, Birchall J, Gray A et al. Guideline on the Investigation and Management of Acute Transfusion Reactions Prepared by The BCSH Blood Transfusion Task Force. *Br J Haematol* 2012;159: 143-153.
132. Tinmouth A. Evidence for a Rational Use of Frozen Plasma for the Treatment and Prevention of Bleeding. *Transfus Aph Sci* 2012;46: 293-298.
133. Treleaven J, Gennery A, Marsh J et al. Guidelines on the Use of Irradiated Blood Components Prepared by the British Committee for Standards in Haematology Blood Transfusion Task Force. *Br J Haematol* 2011; 152.1 : 35-51.
134. Vamvakas EC, Blajchman MA. Transfusion-Related Mortality: The Ongoing Risks of Allogeneic Blood Transfusion and the Available Strategies for their Prevention. *Blood* 2009; 113: 3406-3417.
135. Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transfusion transmission of cytomegalovirus? A review of the literature and a meta-analysis. *Transfus Med Rev* 2005; 19: 181-199.
136. Vichinsky EP. The Prevention and Management of Alloimmunization in Sickle Cell Disease: The Benefit of Extended Phenotypic Matching of Red Blood Cells. *Immunohematology* 2012; 28.1: 20-23.
137. Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin induced thrombocytopenia, 2nd ed. *Br J Haematol*, 2012;159:528-540.
138. Winkler AM, Josephson CD. Transfusion Practices for Patients with Sickle Cell Disease at Major Academic Medical Centers Participating in the Atlanta Sickle Cell Consortium. *Immunohematology* 2012; 28: 24-26.
139. Yang L, Stanworth S, Hopewell S et al. Is Fresh-Frozen Plasma Clinically Effective? An Update of a Systematic Review of Random Controlled Trials. *Transfusion* 2012; 52: 1673-1686.
140. Yawn BP, Buchanan G, Afenyi-Annan AN et al. management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. *JAMA* 2014; 312: 1033-1048.
141. Yazdanbakhsh K, Ware RE, Norzat-Pirenare F. Red Blood Cell Alloimmunization in Sickle Cell Disease: Pathophysiology, Risk Factors and Transfusion Management. *Blood* 2012; 120.3: 528-537.
142. Young PP, Cotton BA, Goodnough LT. Massive Transfusion Protocols for Patients with Substantial Hemorrhage. *Transfus Med Rev* 2011; 25.4: 293-303.

